RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure –response relationship

ConclusionsNo association was observed between RAM exposure and response, suggesting that the RELAY regimen of RAM 10  mg/kg Q2W with ERL is an optimized, efficacious, and safe first-line treatment for patients with untreated, metastatic, EGFR-mutated NSCLC.Trial registration: ClinicalTrials.gov, NCT02411448.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research